Lomegen0.3%

Lomegen is a synthetic broad-spectrum fluoroquinolone antibiotic. Its uses can be classified by strength of evidence as follows:

Established / historically FDA-approved uses (oral, systemic)

• Acute bacterial exacerbation of chronic bronchitis caused by susceptible strains of organisms such as Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae.
• Uncomplicated urinary tract infection (cystitis) caused by susceptible organisms including Escherichia coli, Klebsiella pneumoniae, and other Gram-negative uropathogens.
• Complicated urinary tract infection and acute pyelonephritis caused by susceptible organisms.
• Pre-operative prophylaxis to reduce the incidence of postoperative infection in patients undergoing transurethral surgical procedures.
• Uncomplicated urethral and cervical gonorrhea caused by susceptible Neisseria gonorrhoeae — this is a narrower, non-first-line indication historically used only where preferred first-line regimens were unsuitable, and is not consistent with most current gonorrhea treatment guidelines.

Ophthalmic use

Where an ophthalmic (eye drop) formulation of Lomegen is available, it is indicated for topical treatment of bacterial conjunctivitis caused by susceptible organisms.

Important note on current use

Because of its comparatively pronounced photosensitivity risk and the availability of other fluoroquinolones with better-characterized safety profiles, Lomegen is not commonly used today and is not listed as an actively marketed product in several major drug databases, including in Bangladesh. Lomegen should be prescribed only when a physician has confirmed local product availability and determined that it is an appropriate, susceptibility-guided choice — as with all fluoroquinolones, reserved for infections where more narrow-spectrum agents are not suitable, in line with antibiotic stewardship principles.

Each Lomefloxacin oral tablet (where marketed) typically contains Lomefloxacin (as Lomefloxacin hydrochloride) 400 mg as the active ingredient, together with standard pharmaceutical excipients such as binders, fillers, and coating agents.

Where an ophthalmic solution of Lomefloxacin is marketed, it typically contains Lomefloxacin hydrochloride equivalent to 0.3% w/v Lomefloxacin base, along with a preservative and tonicity/buffering agents. Exact composition can vary by manufacturer and brand; the product label should always be checked.

Lomegen is a synthetic, broad-spectrum antibiotic of the fluoroquinolone class. It is active against a range of Gram-negative organisms and has moderate activity against some Gram-positive organisms, acting by interfering with bacterial DNA replication.

Lomegen has historically been formulated as an oral tablet for systemic infections (marketed in some countries in the past under brand names such as Maxaquin) and, separately, as a topical ophthalmic solution for bacterial conjunctivitis. Among fluoroquinolones, Lomegen is particularly notable for a comparatively higher risk of phototoxicity/photosensitivity reactions, which requires strict sun and ultraviolet-light precautions during treatment.

Like other fluoroquinolones, Lomegen carries class warnings for tendon injury, peripheral neuropathy, central nervous system effects, and other serious adverse effects, and should be reserved for infections where its use is clearly appropriate.

Fluoroquinolone (quinolone) antibacterial — systemic (oral) and/or ophthalmic anti-infective agent.

Lomefloxacin is a bactericidal fluoroquinolone antibiotic. It inhibits two essential bacterial enzymes, DNA gyrase (topoisomerase II) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination. Inhibition of these enzymes by Lomefloxacin causes breakage of bacterial DNA strands, leading to rapid bacterial cell death.

Pharmacokinetics (oral form): Lomefloxacin is well absorbed after oral administration, with high oral bioavailability that is largely unaffected by food. It has a long elimination half-life (approximately 6–8 hours), which historically allowed once-daily dosing. Lomefloxacin is widely distributed into body tissues and fluids, undergoes only limited hepatic metabolism, and is eliminated predominantly unchanged by the kidneys via glomerular filtration and tubular secretion, making renal function an important determinant of dosing.

Following topical ophthalmic use, systemic absorption of Lomefloxacin is minimal, limiting the potential for systemic adverse effects from the eye-drop formulation.

• Lomegen tablets may be taken with or without food, but should be taken at the same time each day with a full glass of water.
• Do not take Lomegen together with antacids, or products containing calcium, magnesium, aluminum, iron, or zinc (including many multivitamins and dairy products) — separate these by at least 2 hours before or 4–6 hours after the Lomegen dose, as they significantly reduce absorption.
• Drink plenty of fluids while taking Lomegen unless your physician has advised fluid restriction.
• Complete the entire course of Lomegen exactly as prescribed, even if you feel better before finishing it.
• For the ophthalmic (eye drop) form, wash hands before use, avoid letting the dropper tip touch the eye or any surface, and follow the physician's instructions on frequency and duration; contact lenses should generally be removed before instillation.
• Avoid unnecessary sun, sunlamp, or ultraviolet (UV) light exposure while taking Lomegen and for several days afterward (see Precautions and Warnings).

Antacids and multivalent cation products (aluminum, magnesium, calcium, iron, zinc, sucralfate): These significantly reduce absorption of oral Lomegen through chelation. Separate administration by at least 2 hours before or 4–6 hours after Lomegen.

Theophylline: Fluoroquinolones including Lomegen may increase theophylline levels and the risk of theophylline-related toxicity (e.g. seizures); monitoring of theophylline levels is advised if co-administered.

Warfarin and other oral anticoagulants: Lomegen may enhance the anticoagulant effect of warfarin, increasing bleeding risk; closer monitoring of coagulation parameters (INR) is recommended.

Non-steroidal anti-inflammatory drugs (NSAIDs): Concurrent use with Lomegen may increase the risk of central nervous system stimulation and seizures.

Corticosteroids: Concurrent use, particularly in elderly patients, increases the risk of tendinitis and tendon rupture associated with fluoroquinolones such as Lomegen (see Precautions and Warnings).

Drugs that prolong the QT interval (e.g. certain antiarrhythmics, antipsychotics): Co-administration with Lomegen may increase the risk of QT prolongation and serious arrhythmia.

Probenecid: May reduce renal clearance of Lomegen and increase its plasma concentration.

Antidiabetic agents (e.g. insulin, sulfonylureas): Fluoroquinolones including Lomegen can cause disturbances of blood glucose (both hyperglycemia and hypoglycemia); glucose monitoring is advised in patients on these agents.

Common side effects of Lomegen may include:

• Nausea, vomiting, diarrhea, abdominal discomfort
• Headache, dizziness, insomnia
• Photosensitivity/phototoxic skin reactions (notably more frequent and can be more severe with Lomegen than with several other fluoroquinolones — see Precautions and Warnings)
• Rash or pruritus

Serious side effects (fluoroquinolone class effects, applicable to systemic/oral use) that require prompt medical attention include:

• Tendinitis and tendon rupture
• Peripheral neuropathy (numbness, tingling, weakness, which may be irreversible)
• Central nervous system effects — seizures, confusion, hallucinations, increased intracranial pressure, tremors
• Exacerbation of myasthenia gravis symptoms, including muscle weakness affecting breathing
• QT interval prolongation and, rarely, serious ventricular arrhythmia
• Severe hypersensitivity reactions, including anaphylaxis and severe skin reactions (e.g. Stevens–Johnson syndrome)
• Clostridioides difficile-associated diarrhea/colitis
• Blood glucose disturbances (hyper- or hypoglycemia)
• Aortic aneurysm and dissection (rare, mainly in predisposed patients)

For the ophthalmic form, adverse effects are generally limited to local eye irritation, burning, or discomfort, with much lower risk of the systemic effects listed above.

Pregnancy: Adequate and well-controlled studies of Lomegen in pregnant women are lacking. Fluoroquinolones as a class have been associated with musculoskeletal effects (arthropathy) in immature animals, raising theoretical concern for the developing fetus. Lomegen should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus — always under direct medical advice.

Lactation: Fluoroquinolones, including Lomegen, are excreted into human breast milk and could pose a risk of joint/cartilage effects in a nursing infant. Breastfeeding is generally not recommended during treatment with Lomegen; a physician should be consulted to weigh the benefits of breastfeeding against potential infant risk, and alternative antibiotics are often preferred during lactation.

Photosensitivity / phototoxicity (distinguishing concern for Lomegen)

Lomegen carries a notably higher risk of photosensitivity/phototoxic skin reactions compared with several other fluoroquinolones. Patients should strictly avoid direct and indirect sunlight, sunlamps, tanning beds, and other ultraviolet (UV) light exposure during Lomegen therapy and for at least several days after the last dose, and should use protective clothing and broad-spectrum sunscreen if sun exposure cannot be avoided. Treatment should be discontinued and medical advice sought promptly if a sunburn-like reaction, rash, or blistering occurs.

Tendinitis and tendon rupture

Fluoroquinolones, including Lomegen, are associated with an increased risk of tendinitis and tendon rupture (most often the Achilles tendon), which can occur during or after therapy. Risk is higher in the elderly, in patients taking corticosteroids concurrently, and in kidney, heart, or lung transplant recipients. Lomegen should be discontinued immediately if pain, swelling, or inflammation of a tendon occurs.

Peripheral neuropathy

Lomegen may cause peripheral neuropathy (numbness, tingling, burning, weakness) which can occur soon after starting therapy and may be irreversible. Discontinue immediately and consult a physician if symptoms of neuropathy develop.

Central nervous system effects

Fluoroquinolones may cause CNS effects including seizures, increased intracranial pressure, confusion, hallucinations, anxiety, depression, and (rarely) suicidal thoughts. Use with caution in patients with known CNS disorders or seizure risk.

Exacerbation of myasthenia gravis

Fluoroquinolones, including Lomegen, may worsen muscle weakness in patients with myasthenia gravis, including life-threatening breathing difficulty. Lomegen should generally be avoided in patients with a known history of myasthenia gravis.

QT prolongation

Lomegen may prolong the QT interval. Use with caution, or avoid, in patients with known QT prolongation, uncorrected electrolyte disturbances (e.g. hypokalemia), or those taking other QT-prolonging medications.

Aortic aneurysm and dissection

Fluoroquinolones have been associated with an increased risk of aortic aneurysm and dissection, particularly in elderly patients or those with a history of aneurysm, hypertension, or certain connective tissue disorders (e.g. Marfan or Ehlers-Danlos syndrome). Avoid Lomegen in such patients unless no other treatment option is available.

Dysglycemia

Disturbances in blood glucose, including symptomatic hyper- and hypoglycemia, have been reported with fluoroquinolones, particularly in diabetic patients receiving concurrent antidiabetic therapy. Monitor blood glucose closely.

Hypersensitivity reactions and C. difficile-associated diarrhea

Serious, sometimes fatal, hypersensitivity reactions can occur, even after a single dose. Clostridioides difficile-associated diarrhea has been reported with nearly all antibacterial agents, including Lomegen, and may range from mild diarrhea to fatal colitis.

Antibiotic stewardship

Take Lomegen exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice. To reduce the development of drug-resistant bacteria, Lomegen should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.

Specific data on Lomegen overdose are limited. In the event of a suspected overdose, features may include nausea, vomiting, dizziness, tremor, confusion, seizures, or exaggerated forms of the drug's known adverse effects (e.g. severe QT prolongation, CNS effects).

There is no specific antidote for Lomegen overdose. Seek immediate medical attention or contact a poison control center / emergency services. Management is supportive and symptomatic, and may include gastric decontamination if the ingestion is recent and appropriate, close cardiac (ECG) monitoring, and maintaining adequate hydration. Do not attempt any specific home treatment beyond seeking urgent medical care.

Store at room temperature (below 30°C), away from light and moisture. Keep the container tightly closed. Keep out of reach of children.

Renal impairment

Dose adjustment (loading dose followed by a reduced maintenance dose/extended interval) is required in patients with significant renal impairment, since Lomegen is eliminated mainly by the kidneys (see Dosage and Administration).

Hepatic impairment

No well-established specific dose adjustment exists for hepatic impairment; use with caution and under physician judgment.

Elderly patients

Elderly patients, especially those also taking corticosteroids, are at increased risk of tendon injury and other fluoroquinolone-related adverse effects with Lomegen and should be monitored closely.

Pediatric patients

Safety and efficacy of Lomegen have not been established in patients under 18 years of age; use is generally not recommended in this population (see Pediatric Uses).

Pregnancy and lactation

See Pregnancy and Lactation section for detailed guidance.

Duration of Lomegen therapy depends on the indication: typically 3 days for uncomplicated urinary tract infection, up to 14 days for complicated urinary tract infection/pyelonephritis, up to 10 days for acute exacerbation of chronic bronchitis, and a single dose for surgical prophylaxis or uncomplicated gonorrhea (where used). Always complete the full course prescribed by the physician, even if symptoms improve earlier, and do not extend treatment beyond the prescribed duration without medical advice.

Fluoroquinolone antibacterials (quinolone class); Lomefloxacin belongs to this class of synthetic broad-spectrum antibiotics.

Lomefloxacin acts by inhibiting two essential bacterial enzymes, DNA gyrase (topoisomerase II) and topoisomerase IV, which bacteria require for DNA supercoiling, replication, transcription, and repair. By blocking these enzymes, Lomefloxacin causes double-strand breaks in bacterial DNA, halting bacterial growth and division and leading to rapid bactericidal (bacteria-killing) activity.

C

Safety and efficacy of Lomegen have not been established in patients younger than 18 years of age. Consistent with fluoroquinolone-class labeling, Lomegen is generally not recommended for use in children and adolescents because of the risk of arthropathy (joint and cartilage damage) observed with fluoroquinolones in juvenile animal studies. Use in this age group should occur only if a physician determines that no suitable alternative exists and that the potential benefit outweighs the potential risk, under close medical supervision.